C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience hemolysis and require RBC transfusions despite receiving treatment with eculizumab Louisville, Ky., December 20, 2016 – Apellis Pharmaceuticals, Inc., a…
Glasgow, Scotland, and Sheffield, UK, 12th December 2016 – Mironid Ltd, a leader in cell signalling-directed drug development, and the University of Sheffield, announced today that they have signed a collaboration agreement to identify and develop new molecules for the treatment of Autosomal Dominant Polycystic…
Mironid is delighted to announce that Prof Albert Ong DM MA FRCP, Professor of Renal Medicine, Department of Infection Immunity & Cardiovascular Disease, University of Sheffield has joined our Scientific Advisory Board. Albert brings enormous experience of the molecular, cellular and clinical aspects of Autosomal…
Louisville, Ky., December 2, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim results from two ongoing Phase Ib open-label, dose-escalation clinical trials of APL-2, a complement C3 inhibitor, in paroxysmal nocturnal hemoglobinuria…